Evidence map›Paper›PMID 37291336›Full record

ArticleNature neuroscience2023

Identification of a protective microglial state mediated by miR-155 and interferon-γ signaling in a mouse model of Alzheimer's disease.

Zhuoran Yin, Shawn Herron, Sebastian Silveira, Kilian Kleemann, Christian Gauthier, Dania Mallah, Yiran Cheng, Milica A Margeta, Kristen M Pitts, Jen-Li Barry and 13 more

Open access · greenAbstract read
In one paragraph

Article in Nature neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Immune dysfunction in Alzheimer disease.Nature reviews. Neuroscience · 2026
    Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 3 countries.

Zhuoran Yin *Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Shawn Herron *Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Sebastian SilveiraDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Kilian KleemannDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2753-6804
Christian GauthierDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Dania MallahDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Yiran ChengDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5589-2024
Milica A MargetaDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Kristen M PittsDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7049-0883
Jen-Li BarryDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ayshwarya SubramanianKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4134-7612
Hannah ShoreyDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Wesley BrandaoDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ana DuraoDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jean-Christophe DelpechDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Charlotte MadoreDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Mark JedrychowskiDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, MA, USA.
Amrendra K AjayDepartment of Medicine, Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2790-5726
Gopal MurugaiyanDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Samuel W HershDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Seiko IkezuDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Tsuneya IkezuDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA. ikezu.tsuneya@mayo.edu.ORCID http://orcid.org/0000-0002-3979-8596
Oleg ButovskyDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. obutovsky@rics.bwh.harvard.edu.ORCID http://orcid.org/0000-0003-0186-8867
Brigham and Women's Hospital · USBoston University · USBroad Institute · USHarvard University · US

Funding

Mass Eye and Ear-Vision Clinical Scientist Development ProgramK12EY016335 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Reza Dana · 2004 to 2026
$12.3M
TRAINING IN BIOMOLECULAR PHARMACOLOGYT32GM008541 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARB, DAVID H · 1997 to 2022
$5.2M
Exosome-mediated propagation of pathogenic tau proteinRF1AG054199 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2016 to 2021
$5.0M
Targeting TGFb/IFNy-IRF8 Signaling to Modulate Monocytes and their Crosstalk with Microglia and Astrocytes to Treat Multiple SclerosisR01NS088137 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI Oleg Butovsky · 2014 to 2026
$4.9M
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer’s diseaseR01AG054672 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BUTOVSKY, OLEG, IKEZU, TSUNEYA · 2017 to 2021
$4.1M
Sex-dependent APOE4 regulation of neutrophil-microglia crosstalk in Alzheimer's diseaseR01AG075509 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI Oleg Butovsky · 2022 to 2026
$3.6M
Role of a novel risk loci HAVCR2 of late-onset Alzheimer's disease in the regulation of microglial response in neurodegenerationR01AG080992 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI Oleg Butovsky, VIJAY K. KUCHROO · 2023 to 2026
$3.3M
Molecular characterization of extracellular vesicles for the spread of misfolded tau proteinR01AG067763 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2021 to 2025
$3.1M
Microglial mechanisms of postoperative CNS inflammation and cognitive declineR01AG051812 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BUTOVSKY, OLEG, CROSBY, GREGORY · 2016 to 2020
$2.7M
Cognition and the immunology of postoperative outcomesR01GM132668 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI CULLEY, DEBORAH J · 2019 to 2024
$2.7M
Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse modelR01AG072719 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2021 to 2025
$2.7M
Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimer’s diseaseR01AG079859 · NIA · MAYO CLINIC JACKSONVILLE · PI Seiko Ikezu · 2023 to 2026
$2.2M
NEI NIH HHS K08 EY030160NEI NIH HHS K12 EY016335NEI NIH HHS R01 EY027921NIA NIH HHS F31 AG071106NIA NIH HHS R01 AG051812NIA NIH HHS R01 AG054199NIA NIH HHS R01 AG054672NIA NIH HHS R01 AG066429NIA NIH HHS R01 AG067763NIA NIH HHS R01 AG072719NIA NIH HHS R01 AG075509NIA NIH HHS R01 AG079859NIA NIH HHS R01 AG080992NIA NIH HHS R21 AG076982NIA NIH HHS R41 AG073059NIA NIH HHS RF1 AG054199NIGMS NIH HHS R01 GM132668NIGMS NIH HHS T32 GM008541NINDS NIH HHS R01 NS088137NINDS NIH HHS R21 NS101673NINDS NIH HHS R21 NS104609
6 · The paper itself

Abstract

Microglia play a critical role in brain homeostasis and disease progression. In neurodegenerative conditions, microglia acquire the neurodegenerative phenotype (MGnD), whose function is poorly understood. MicroRNA-155 (miR-155), enriched in immune cells, critically regulates MGnD. However, its role in Alzheimer's disease (AD) pathogenesis remains unclear. Here, we report that microglial deletion of miR-155 induces a pre-MGnD activation state via interferon-γ (IFN-γ) signaling, and blocking IFN-γ signaling attenuates MGnD induction and microglial phagocytosis. Single-cell RNA-sequencing analysis of microglia from an AD mouse model identifies Stat1 and Clec2d as pre-MGnD markers. This phenotypic transition enhances amyloid plaque compaction, reduces dystrophic neurites, attenuates plaque-associated synaptic degradation and improves cognition. Our study demonstrates a miR-155-mediated regulatory mechanism of MGnD and the beneficial role of IFN-γ-responsive pre-MGnD in restricting neurodegenerative pathology and preserving cognitive function in an AD mouse model, highlighting miR-155 and IFN-γ as potential therapeutic targets for AD.

Indexed as

Alzheimer DiseaseMicroRNAsAmyloid beta-PeptidesAnimalsDisease Models, AnimalInterferon-gammaMiceMice, TransgenicMicrogliaPlaque, AmyloidSignal TransductionAmyloid beta-PeptidesInterferon-gammaMicroRNAsMirn155 microRNA, mouse

Identifiers

PMID37291336
PMCPMC10619638
OpenAlexW4379878477

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.